drugset / Trial / NCT01505179

The Effects of Ranolazine on Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction

NCT01505179

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether treatment with Ranolazine will improve exercise capacity in patients with Heart Failure with preserved left ventricular ejection fraction, or HFPEF.

Timeline

Start
2011-02
Primary completion
2014-12
Completion
2015-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ranolazine Small molecule 500 mg Oral
Comparator Ranolazine Small molecule 1000 mg Oral